Chemotherapy Immunotherapy
Chemotherapy Immunotherapy - Related Videos
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
0 Views •
Cited by 28 •
2012
This abstract describes a novel method to assess the development of neurotoxicity in patients receiving chemotherapy treatment. While conventional assessment methods are limited in their ability to detect early changes in nerve function, nerve excitability techniques provide early identification of patients at risk of severe neurotoxicity and insight into pathophysiology.
01:27
Tumor Immunotherapy
0 Views •
2024
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
0 Views •
Cited by 15 •
2016
The current report summarizes a protocol that can be utilized to model the influence of the bone marrow microenvironment niche on leukemic cells with emphasis placed on enrichment of the most chemoresistant subpopulation.
08:06
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
0 Views •
Cited by 21 •
2010
An experimental lung metastasis and CTL immunotherapy mouse model for analysis of tumor cells-T cell interaction in vivo.
05:01
Multiplexed Immunofluorescence Imaging to Analyze Immunotherapy-Resistant T Cell Subpopulations
0 Views •
2025
This video demonstrates an in-situ fluorescence multispectral imaging technique to analyze different subpopulations of infiltrating T cells in tumor tissue. A renal cell carcinoma tissue cryosection is treated with antibodies to label CD8+ T cells that express specific inhibitory receptors and exhibit an immunotherapy-resistant phenotype. The labeled section is visualized using a multispectral microscope to identify the distinct CD8+ T cell subpopulations.
FAQs
Beyond directly damaging rapidly dividing cells, chemotherapy can increase the release of tumor antigens, which are recognizable markers from malignant cells. It may also reduce immunosuppressive cells that limit immune activity. These changes can make tumor tissue more visible or accessible to immune-based treatment, providing a mechanistic rationale for combining the two approaches.
The order and dose of each treatment can influence how chemotherapy-related tumor changes interact with immune activation. Cancer studies therefore compare different sequencing strategies and dosing plans rather than assuming that simultaneous or fixed administration is optimal. Examining these variables helps researchers identify regimens that support stronger responses while clarifying how treatment design affects outcomes.
Biomarkers help researchers investigate which patients are more likely to benefit from combined treatment. In this setting, they are studied alongside tumor response, treatment sequencing, dosing, and resistance mechanisms. Their purpose is not simply to describe a tumor, but to connect measurable biological features with the likelihood of response, durability, or limited benefit.
Resistance is examined as a biological and treatment-related problem that can limit the effectiveness of the combination. Studies evaluate whether resistance is associated with immune response, chemotherapy exposure, treatment sequence, dose, or characteristics of the tumor. This analysis can reveal why an initially promising regimen fails to produce durable control and can guide further treatment comparisons.
The strategy is evaluated across both blood cancers and solid tumors, allowing researchers to examine its relevance in different cancer settings. Studies can compare response rates, durability, patient outcomes, biomarkers, and resistance patterns across these broad groups. This wider research scope helps determine whether findings apply generally or remain specific to particular tumor contexts.
Key outcomes include response rates, the durability of those responses, and broader patient outcomes. Researchers interpret these measures together with treatment dose, sequence, biomarkers, and resistance mechanisms. A regimen that produces an initial response may still require evaluation of how long that response persists, making durability an important complement to short-term tumor control.
It is relevant when investigators want to test whether chemotherapy and immune-based treatment can produce better or more lasting results together than either mechanism might support alone. Research focuses on identifying suitable patients, refining sequence and dose, and understanding resistance across blood cancers and solid tumors. These studies aim to improve response rates, durability, and patient outcomes.